Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$5.38 USD
+0.27 (5.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $5.36 -0.02 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.38 USD
+0.27 (5.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $5.36 -0.02 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Anavex Life Sciences (AVXL) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Why Anavex Life Sciences (AVXL) Might Surprise This Earnings Season
by Zacks Equity Research
Anavex Life Sciences (AVXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.
Implied Volatility Surging for Anavex Life Sciences (AVXL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Anavex Life Sciences (AVXL) stock based on the movements in the options market lately.
Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B
by Zacks Equity Research
Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.
Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes
by Zacks Equity Research
Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.
Incyte (INCY) Gets Positive CHMP Opinion for Pemigatinib
by Zacks Equity Research
Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.
Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.
Illumina (ILMN) New Collaboration to Aid Genomics Startups
by Zacks Equity Research
Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.
Global Blood's (GBT) MAA for Oxbryta Accepted in Europe
by Zacks Equity Research
Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.
Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA
by Zacks Equity Research
Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
by Zacks Equity Research
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's Why
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Anavex (AVXL) in Focus: Stock Moves 9.5% Higher
by Zacks Equity Research
Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
PPD Looks Good: Stock Adds 5.2% in Session
by Zacks Equity Research
PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Axonics (AXNX) Looks Good: Stock Adds 7.4% in Session
by Zacks Equity Research
Axonics (AXNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Personalis (PSNL) Looks Good: Stock Adds 8% in Session
by Zacks Equity Research
Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Principia (PRNB) Looks Good: Stock Adds 9.4% in Session
by Zacks Equity Research
Principia (PRNB) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Adverum (ADVM) Surges: Stock Moves 6.2% Higher
by Zacks Equity Research
Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AVXL) Outperforming Other Medical Stocks This Year?
Anavex Life Sciences (AVXL) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.